+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cancer/Tumor Profiling - Global Market Trajectory & Analytics

  • PDF Icon

    Report

  • 239 Pages
  • April 2021
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 4804691
Global Cancer/Tumor Profiling Market to Reach $11.6 Billion by 2027

Amid the COVID-19 crisis, the global market for Cancer/Tumor Profiling estimated at US$6.2 Billion in the year 2020, is projected to reach a revised size of US$11.6 Billion by 2027, growing at a CAGR of 9.3% over the analysis period 2020-2027. Immunoassays, one of the segments analyzed in the report, is projected to record a 9.1% CAGR and reach US$3.6 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Hybridization segment is readjusted to a revised 9.7% CAGR for the next 7-year period.



The U.S. Market is Estimated at $1.8 Billion, While China is Forecast to Grow at 8.7% CAGR

The Cancer/Tumor Profiling market in the U.S. is estimated at US$1.8 Billion in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$2 Billion by the year 2027 trailing a CAGR of 8.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.5% and 7.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.6% CAGR.

Next Generation Sequencing Segment to Record 10.1% CAGR

In the global Next Generation Sequencing segment, USA, Canada, Japan, China and Europe will drive the 10.2% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$864.8 Million in the year 2020 will reach a projected size of US$1.7 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.3 Billion by the year 2027.

Select Competitors (Total 44 Featured):
  • Caris Life Sciences
  • Genomic Health, Inc.
  • Helomics Corporation
  • HTG Molecular Diagnostics, Inc.
  • Illumina, Inc.
  • Nanostring Technologies, Inc.
  • NeoGenomics Laboratories, Inc.
  • Oxford Gene Technology
  • Qiagen NV
  • Ribomed Biotechnologies, Inc.
Frequently Asked Questions about the Global Market for Cancer/Tumor Profiling

What is the estimated value of the Global Market for Cancer/Tumor Profiling?

The Global Market for Cancer/Tumor Profiling was estimated to be valued at $6.2 Billion in 2020.

What is the growth rate of the Global Market for Cancer/Tumor Profiling?

The growth rate of the Global Market for Cancer/Tumor Profiling is 9.4%, with an estimated value of $11.6 Billion by 2027.

What is the forecasted size of the Global Market for Cancer/Tumor Profiling?

The Global Market for Cancer/Tumor Profiling is estimated to be worth $11.6 Billion by 2027.

Table of Contents

I. METHODOLOGY

II. EXECUTIVE SUMMARY
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Cancer/Tumor Profiling: Market Overview & Outlook
  • Impact of Covid-19 and a Looming Global Recession
  • Increasing Incidence of Cancer Worldwide: Primary Growth Driver
  • Exhibit 1: Cancer Rates (100,000 People) in Select Countries: 2021
  • Exhibit 2: Estimated New Cancer Cases & Deaths in the US by Sex: 2020
  • Exhibit 3: Estimated Number of New Cancer Cases in Men by Cancer Type: 2020
  • The United States: Characterized by Higher Incidence of Cancer
  • Exhibit 4: Estimated New Cancer Cases & Deaths in the US by Sex: 2020
  • Exhibit 5: Estimated New Cases for Selected Cancers in the US by State: 2020
  • Enhanced Use of Biomarkers in Tumor Profiling Bodes Well
  • Cancer Research & Funding Initiatives Augment Market Prospects
  • Growing Role of Personalized Medicine Augurs Well
  • Advances in Point-of-Care Cancer Diagnostics to Accelerate Uptake

III. MARKET ANALYSIS

IV. COMPETITION
  • Total Companies Profiled: 44